By examining the basic indicators for Veru and Seres, you can assess how market fluctuations impact their stock prices and determine if combining them in a portfolio might reduce overall risk. Consider using a pair trading strategy by taking a long position in Seres and a short position in Veru. For more insights, explore our [pair correlation module](link) for detailed analysis.
Now, let's dive into the assets. The asset utilization ratio measures how effectively a company generates revenue from its assets. Veru's ratio stands at 27.95%, meaning it earns $0.28 for every dollar of assets. A rising asset utilization ratio indicates that Veru Inc is improving its efficiency in using assets for daily operations.
Important Points
Trading Veru Inc stock presents a mixed bag for investors, with its current quote at
0.51 reflecting a slight price change of
-0.01, suggesting a degree of volatility. Despite the challenges indicated by a profit margin loss of 2.28, the company's cash flow of
24.9M provides a cushion, hinting at potential resilience in the face of market fluctuations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as Veru or BioXcel is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is Veru's Liquidity
Veru
financial leverage refers to using borrowed capital as a funding source to finance Veru Inc ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Veru financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Veru's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Veru's financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Veru's total debt and its cash.
Correlation Between Veru and BioXcel Therapeutics
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding Veru together with similar or unrelated positions with a negative correlation. For example, you can also add BioXcel Therapeutics to your portfolio. If BioXcel Therapeutics is not perfectly correlated to Veru it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When Veru, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both Veru and BioXcel Therapeutics in your portfolio? Please note if you are using this as a pair-trade strategy between Veru and BioXcel Therapeutics, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between VERU and BTAI for more information.
A Deeper Perspective
Total Debt Breakdown
Lets now check Veru total debt. Based on the latest financial disclosure, Veru Inc has a Total Debt of 13.86
M. This is 99.5% lower than that of the Personal Care Products sector and 95.73% lower than that of the
Consumer Staples industry. The total debt for all United States stocks is 99.74% higher than that of the firm.
As for Seres Therapeutics we see total debt of 91.64
M, which is 71.78% lower than that of the Consumer Staples
| VERU | 13.86 Million | 3.22 |
| Sector | 324.78 Million | 75.48 |
| MCRB | 91.64 Million | 21.3 |
Warren Buffett once said, "Risk comes from not knowing what you're doing." When comparing Veru Inc to Seres Therapeutics, investors should be mindful of the distinct risk profiles each company presents. Veru Inc, with a market capitalization of $75.24 million and a high probability of bankruptcy at 89.07%, poses significant financial risks. Despite a current ratio of 4.62X indicating short-term financial health, the company's negative EBITDA of 40.7 million and a diluted EPS of 0.21 highlight ongoing operational challenges. In contrast, Seres Therapeutics may offer a different risk-reward balance, making it crucial for investors to thoroughly assess their risk tolerance and investment strategy before making a decision..
Will Veru drop impact its fundamentals?
Veru Inc's stock has taken a notable hit, with its coefficient of variation dropping to -4656.71, indicating increased volatility and potential instability. While this decline might raise concerns about the company's market standing, it's important to assess whether this volatility truly reflects issues within Veru's core operations. Investors should delve into the company's financial health, strategic plans, and market environment to determine if the recent stock fluctuations are just a temporary market reaction or signal deeper problems.
Veru Inc is classified as a potential penny stock, characterized by low volatility, a skewness of 2.37, and a kurtosis of 12.1. While investing in Veru might seem appealing, penny stocks are often speculative and prone to artificial price inflation. It's crucial to understand both the potential gains and risks. Be wary of signs like email spams, message board hype, sudden news releases, and unreported promotions. Investigate the backgrounds of current and former company officers before investing in high-volatility stocks.
While timing your entry and exit perfectly can yield profits, remember that artificially hyped penny stocks often fail to sustain their price surge. Sustainable shareholder value comes from genuine performance supported by strong fundamentals.Investing in Veru Inc. presents a mix of potential and uncertainty. While the stock has faced challenges, the analyst consensus leans towards optimism, with a "Strong Buy" rating supported by two strong buy recommendations. The highest estimated target price of
3.61 suggests room for growth, especially if the company can capitalize on its strategic initiatives. However, with a possible downside price of
0.0051, it's crucial for investors to weigh the risks carefully. As with any investment, keeping an eye on market trends and company developments will be key to making informed decisions..
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Prophet is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ProphetEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Veru Inc. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
